School of Population and Public Health, University of British Columbia, 2206 E Mall, Vancouver, BC V6T 1Z3, Canada.
School of Population and Public Health, University of British Columbia, 2206 E Mall, Vancouver, BC V6T 1Z3, Canada; Centre for Health Evaluation and Outcome Sciences, 588-1081 Burrard Street, St. Paul's Hospital, Vancouver, BC V6Z 1Y6, Canada.
Vaccine. 2020 Dec 14;38(52):8396-8404. doi: 10.1016/j.vaccine.2020.10.033. Epub 2020 Nov 22.
Current human papillomavirus (HPV) vaccine coverage in the United States (in 2019, 66-70%), remains below the Healthy People 2020 coverage goal of 80%. HPV vaccine misinformation, including parental concerns of sexual risk-compensation influence vaccine uptake. We examined the association between HPV vaccination and sexually transmitted infection (STI) outcomes.
Of the 20,146 participants from 2013 to 2014 and 2015-2016 cycles of the National Health and Nutrition Examination Survey, 1050 females aged 18-35 with a history of sexual activity had complete case data. Roa-Scott Chi-squared and F-tests assessed survey-weighted socio-demographic differences between vaccinated and unvaccinated participants. Weighted logistic regression assessed crude and adjusted associations between self-reported HPV vaccination (none vs. ≥ 1dose) and lab-confirmed STIs (trichomonas and chlamydia) and vaccine-type HPV (6/11/16/18). As a sensitivity analysis, we conducted weighted-propensity score (PS) models and inverse probability weighting by vaccination status. PS and logistic regression were estimated through survey-weighted logistic regression on variables including race, education, income, marital status, US citizenship, cycle year and age.
Overall, 325 (31.8%) females with a history of sexual activity were HPV vaccinated, of which 22 (6.1%) received the vaccine at the routine-recommended ages of 11-12, 65.7% were vaccinated after their self-reported sexual debut, 3.8% had a lab-confirmed STI and 3.5% had vaccine-type HPV. There was no association between HPV vaccination and any STIs (adjusted odds ratio [aOR] 0.67, 95%CI:0.38-1.20), and vaccinated participants had 61% reduced odds of vaccine-type HPV (vs. unvaccinated; aOR 0.39, 95%CI:0.19-0.83). Results from the PS sensitivity analysis were similar to the main findings.
Among females who reported a history of sexual activity, HPV vaccination status was protective against vaccine-type HPV and not associated with lab-based STI outcomes. Although findings may be susceptible to reporting bias, results indicating low vaccine uptake at routine-recommended ages requires additional efforts promoting HPV vaccination before sexual-debut.
目前美国的人乳头瘤病毒(HPV)疫苗接种率(2019 年为 66-70%)仍低于“健康人民 2020”计划中 80%的目标。HPV 疫苗错误信息,包括父母对性风险补偿的担忧,影响了疫苗接种率。我们研究了 HPV 疫苗接种与性传播感染(STI)结果之间的关系。
在 2013 年至 2014 年和 2015 年至 2016 年全国健康和营养调查周期中,有 20146 名参与者,其中有 1050 名 18-35 岁有过性行为史的女性有完整的病例数据。Roa-Scott 卡方检验和 F 检验评估了接种疫苗和未接种疫苗参与者之间基于调查权重的社会人口统计学差异。加权逻辑回归评估了自我报告的 HPV 疫苗接种(无 vs.≥1 剂)和实验室确诊的 STI(滴虫和衣原体)与疫苗型 HPV(6/11/16/18)之间的粗关联和调整关联。作为敏感性分析,我们通过接种疫苗状态进行了加权倾向评分(PS)模型和逆概率加权。PS 和逻辑回归通过对包括种族、教育、收入、婚姻状况、美国公民身份、周期年份和年龄在内的变量进行基于调查权重的逻辑回归进行估计。
总体而言,有 325 名(31.8%)有性行为史的女性接种了 HPV 疫苗,其中 22 名(6.1%)在常规推荐的 11-12 岁时接种了疫苗,65.7%在自我报告的性行为后接种了疫苗,3.8%有实验室确诊的 STI,3.5%有疫苗型 HPV。HPV 疫苗接种与任何 STI 均无关联(调整后的优势比[aOR]0.67,95%CI:0.38-1.20),接种组的疫苗型 HPV 发生几率降低了 61%(与未接种组相比;aOR 0.39,95%CI:0.19-0.83)。PS 敏感性分析的结果与主要发现相似。
在报告有性行为史的女性中,HPV 疫苗接种状况可预防疫苗型 HPV,与基于实验室的 STI 结果无关。尽管结果可能容易受到报告偏倚的影响,但在常规推荐年龄接种率较低的结果表明,在性行为开始前需要进一步努力促进 HPV 疫苗接种。